PRMT5 and hepatocellular carcinoma: Importantly, functionally, silencing PRMT5, MEP50, WDR5 or treatment with OICR-9429 significantly profoundly impaired the ability of MYBL1-induced migrated and invasive of HCC cells and MYBL1-transduced HCC cells to induce HUVEC tube formation and migration (Fig. 6F, G and Supplementary Fig. 4B–E).